Sam Colella of Versant Ventures, Risa Stack of Kleiner Perkins and Alex de Winter of Mohr Davidow join me for the Molecular Diagnostics World Congress Event on September 29 at 5:15pm

John SteuartMDWC2011Successful venture capital investing in molecular diagnostics requires proper commercialization of . But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment.

These challenges include the cost-efficient development of technology that is truly disruptive yet cost-competitive. Panelists will discuss how to best determine the size of a market and how to assess a competitive landscape.

that surmount these challenges then have to weigh the best route to capitalize on the investment, typically via acquisition or an . While IPOs are typically most desired, VCs will discuss why acquisitions are far more common, as well as the pros and cons of guiding the development of a startup for an eventual sale.

See more information about the 4th annual Molecular Diagnostics World Congress, this year's event takes place at the South San Francisco Conference Center.